Comparison of Percutaneous Coronary Intervention, Coronary Artery Bypass Grafting and Medical Therapy in Non-ST Elevation Acute Coronary Syndrome Patients With 3-Vessel Disease

Circ J. 2020 Sep 25;84(10):1718-1727. doi: 10.1253/circj.CJ-20-0300. Epub 2020 Aug 26.

Abstract

Background: The aim of this study is to compare the long-term prognosis of non-ST elevation acute coronary syndrome (NSTE-ACS) patients with 3-vessel disease (3VD) who underwent percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG) or medical therapy (MT).Methods and Results:Overall, 3,928 NSTE-ACS patients with 3VD were consecutively enrolled from April 2004 to February 2011 at Fu Wai Hospital. Patients were followed up for a median of 7.5 years, and were divided into PCI, CABG or MT groups according to their treatment. Compared with patients undergoing PCI, CABG patients had lower rates of myocardial infarction (MI), unplanned revascularization, major adverse cardiovascular and cerebrovascular events (MACCE) and a higher rate of stroke (all P<0.05). Compared with MT, PCI and CABG had lower incidences of all adverse outcomes (all P<0.05), except for a similar rate of stroke between PCI and MT. Kaplan-Meier analysis showed similar results. After adjusting for confounders, CABG was independently associated with a lower risk of cardiac death, revascularization and MACCE compared with PCI (all P<0.05). Compared with MT, PCI reduced long-term risk of death, whereas CABG reduced long-term risk of death, revascularization and MACCE events (all P<0.05).

Conclusions: In NSTE-ACS patients with 3VD, CABG is independently associated with a lower risk of long-term cardiac death, revascularization and MACCE compared with PCI. Patients who received MT alone had the highest risk of long-term MACCE.

Keywords: 3-vessel coronary artery disease; Acute coronary syndrome; Coronary artery bypass grafting; Medical therapy; Percutaneous coronary intervention.

Publication types

  • Comparative Study
  • Observational Study

MeSH terms

  • Acute Coronary Syndrome / complications*
  • Acute Coronary Syndrome / drug therapy*
  • Acute Coronary Syndrome / surgery
  • Aged
  • Aged, 80 and over
  • Angiotensin Receptor Antagonists / adverse effects*
  • Angiotensin-Converting Enzyme Inhibitors / adverse effects*
  • Calcium Channel Blockers / adverse effects*
  • Coronary Artery Bypass / adverse effects*
  • Coronary Artery Disease / complications*
  • Coronary Artery Disease / drug therapy*
  • Coronary Artery Disease / surgery
  • Female
  • Follow-Up Studies
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects*
  • Incidence
  • Male
  • Middle Aged
  • Myocardial Infarction / chemically induced
  • Myocardial Infarction / mortality
  • Percutaneous Coronary Intervention / adverse effects*
  • Platelet Aggregation Inhibitors / adverse effects*
  • Prospective Studies
  • Risk Factors
  • Stroke / chemically induced
  • Stroke / mortality
  • Treatment Outcome

Substances

  • Angiotensin Receptor Antagonists
  • Angiotensin-Converting Enzyme Inhibitors
  • Calcium Channel Blockers
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Platelet Aggregation Inhibitors